Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)
Jennifer A. Ligibel(Dana-Farber Cancer Institute), Eric P. Winer(University of Vermont), X. Cynthia(Washington University in St. Louis), Ann H. Partridge(Dana-Farber Cancer Institute), Deborah Toppmeyer(Rutgers, The State University of New Jersey), Clifford A. Hudis(American Society of Clinical Oncology), Lisa A. Carey(University of North Carolina at Chapel Hill), Harold J. Burstein(Dana-Farber Cancer Institute), Vera J. Suman(Mayo Clinic in Arizona), Hope S. Rugo(City of Hope), Carey K. Anders(Duke University), William T. Barry(Harvard University), Luke Huebner(Alliance Data (United States))
Cited by 16
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k